Literature DB >> 20337861

Percutaneous mechanical assistance for the failing heart.

Cristiano Freitas de Souza1, Flavio de Souza Brito, Valter Correia De Lima, Antonio Carlos De Camargo Carvalho.   

Abstract

One of the most challenging situations in contemporary medicine is, doubtlessly, the approach and treatment of patients presenting with severe left ventricle failure. Since its first clinical application in patients with cardiogenic shock in 1968, the intraaortic balloon pump (IABP) has been widely accepted by heart failure physicians. Although IABP therapy has been shown to be effective for the support and stabilization of hemodynamically compromised patients, it has failed to promote any improvements in patient outcomes. For this reason, much attention has been invested in the development of external devices that can collaborate with the treatment of this condition. In this context, the percutaneous left ventricle assist device (pLVAD), like TandemHeart (Cardiac Assist, Inc.; Pittsburgh, PA, USA), and, more recently, the Impella 2.5 (Abiomed Europe, Aachen, Germany) has emerged. The purpose of this review is to describe the history of pLVAD, from its beginning, to the other devices currently available, including those created for right ventricle and biventricular support.

Entities:  

Mesh:

Year:  2010        PMID: 20337861     DOI: 10.1111/j.1540-8183.2010.00536.x

Source DB:  PubMed          Journal:  J Interv Cardiol        ISSN: 0896-4327            Impact factor:   2.279


  3 in total

Review 1.  Treatment strategies for patients with an INTERMACS I profile.

Authors:  Walid K Abu Saleh; Odeaa Al Jabbari; Ashrith Guha; Matthias Loebe; Brian A Bruckner
Journal:  Methodist Debakey Cardiovasc J       Date:  2015 Jan-Mar

2.  Short-term mechanical management of cardiogenic shock.

Authors:  Jessica L Brown; Roberta C Bogaev; Jack O'Connell
Journal:  Curr Treat Options Cardiovasc Med       Date:  2011-08

Review 3.  New Insights in the Diagnosis and Treatment of Heart Failure.

Authors:  Giulio Agnetti; Massimo F Piepoli; Giuseppe Siniscalchi; Francesco Nicolini
Journal:  Biomed Res Int       Date:  2015-10-26       Impact factor: 3.411

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.